Children have been killed and maimed by Cervarix jab which is composed of recombinant C-terminally truncated HPV-16 L1 and HPV-18 L1 proteins (20 micrograms each) in virus-like particles (VLPs) adjuvanted with AS04 adjuvant system, composed of an Aluminium Hydroxide Al(OH)3 (500 micrograms) and 3-O-desacyl-4'-MonoPhosphoryl Lipid A (MPL, 50 micrograms).
The HPV-16 and HPV-18 L1 antigens are prepared by recombinant DNA technology using a Baculovirus expression system in Trichoplusia ni cells.1
Cervarix also contains Sodium Chloride (NaCl, salt 4.4 mg), monobasic Sodium Phosphate (NaH2PO4.2 H2O, 624 micrograms) and water for injection.
MPL MonoPhosphoryl Lipid A from E. coli Bacteria
Cervarix contains deliberately added supertoxin MPL derived from E. coli.2
It differs from ordinary supertoxin Lipid A by deletion of a single Phosphate group.
MPL has ludicrously been described as a “detoxified” form of Endotoxin Lipid A and was the first such molecule to be approved in a jab as adjuvant. Read more about the madness.3
Gene Interactions of MPL
MPL causes increased expression of mRNA or protein by action on the following genes:
CALCA mRNA; CAT protein; HMOX1 mRNA; ICAM1 protein; IFNG protein; IL1B protein; IL6 protein; IL12 protein; IL17A protein; IL18 protein; IL22 protein; NFKBIA protein; NOTCH1 mRNA; RELA protein; SELE protein; TLR4 protein; TNF protein; VCAM1 protein
Many readers have a special interest in the above list, so I will expand on some of them later.
Diseases caused by MPL
The US government Comparative Toxicogenomics database is once again a useful guide with 425 Diseases listed with peer-reviewed papers.4
It needs some extra curation, but 80 detailed biochemical pathways for its action have been posted already based on inference from the parent Lipid A.5
Australia DAEN reports
TGA Australia shows a number of systemic Adverse Event reports for Cervarix, all consistent with the Endotoxin.6 The Aluminium causes less immediate reactions, but is of course a Neurotoxin adding to Alzheimer’s and related diseases in later life.
LNP packaging of MPL increases the Damage
Incorporation of MPL in PLGA (poly(lactic-co-glycolic acid) Nanoparticles increases TH1 and pro-inflammatory responses of the Target Dendritic Cells (DCs) in comparison to the non-encapsulated administration of MPL.7
In general the use of Cationic LNPs carrying reactogenic adjuvant is the same approach used for the mRNA jabs8, i.e. deliberate harm induction by attack on DCs, as shown by Figure 1 from Nagy and coworkers.
This Figure is also useful as it gives a fairly accurate idea of the relative size of the DCs (about 10,000 nm) to the LNPs (typically 80 nm).
Arexvy Jab contains Endotoxin MPL
A recent article by Sherri Tenpenny alerts us to another high risk jab from GSK.9 Arexvy is supposed to target Respiratory Syncytial Virus (RSV).
Sherri tells us:
When the two vials are mixed together (reconstituted) each 0.5cc dose contains:
RSVPreF3 antigen 120 mcg
MPL 25 mcg
QS-21 from (tree bark) 25 mcg
Trehalose 14,700 mcg
Sodium Chloride (salt) 4,400 mcg
Potassium dihydrogen phosphate 830 mcg
Dipotassium phosphate 260 mcg
Polysorbate 80 180 mcg
Disodium phosphate anhydrous 150 mcg
DOPC (lipids in lysosome) 500 mcg
Cholesterol 125 mcg
Lots of useful information including free downloads has been kindly provided on HPV jabs.10
I expect a number of people would like to contribute useful information in the comments when they hear of the massive Lipid A content compared to the Covid19 jabs.
Here are some GSK publications on their product where the boast about AS04.
In 2012, GSK showed the huge team involved in Cervarix development in 2 papers n Lancet. I include all the names in the HPV PATRICIA Study Group in case you would like to discuss their contributions.1112
In 2013 they claimed it might have contributed to reduced external genital warts in UK.13 However the efficacy figures should not have helped sales:
Abstract
Background: Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008.
A post hoc analysis of the phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent.
Methods: Vaccine efficacy (VE) at 48 months was assessed against 6-month persistent infection (6MPI) with low-risk HPV types in the total vaccinated cohort (TVC) and in the TVC naive (for 25 HPV types tested) populations.
Results: In the TVC naive cohort, VE against 6MPI (95% confidence interval) was 34.5% (11.3 to 51.8) for HPV-6/11, 34.9% (9.1 to 53.7) for HPV-6, 30.3% (-45.0 to 67.5) for HPV-11, and 49.5% (21.0 to 68.3) for HPV-74.
Conclusions: The HPV-16/18 AS04-adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV-6/11/74), which are responsible for the majority of external GWs, and recently, antibody and cell-mediated immune response to HPV-6/11 have been observed. These findings may help to explain the decrease in external GW diagnoses seen in England.
Alarm Bells when you see the range covering Negative Vaccine efficacy to -45%.
In 2015 they said improved PCR testing for DNA was needed to reveal claimed efficacy.14 And they talked about Final Event-drven analysis.15
In 2016 GSK published a study16 claiming:
“There was no evidence of an increased risk of AD (new onset Autoimmune Disease) in women aged 9 to 25 years after AS04-HPV-16/18 vaccination”.
The authors were based in Belgium, Spain, The Netherlands, UK and USA.
However the headline does not tally with their finding statistically significant Autoimmune Thyroiditis Incidence Rate Ratio (IRR): 3.75 [1.25 to 11.31] for females.
Read more about Endotoxin induced Autoimmune Disease including Thyroiditis.17
February 2025 Update
On 7 January 2025 US FDA issued a warning18 Guillain-Barré Syndrome for Arexvy poison, as relayed by JAMA.19 The warning also applies to Pfizer Abrysvo.
Paid subscriptions are much appreciated.
Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted). TGA Product Information. July 2023
Thomas W Dubensky Jr, Steven G Reed. 2010. Adjuvants for cancer vaccines. Semin Immunol. 22(3):155-61. doi: 10.1016/j.smim.2010.04.007.
Peter Hotez promotes Endotoxin and Neurotoxic Aluminium in Jabs
Some have asked whether recent focus on Peter Hotez is part of a diversionary plan to shift attention away from the weaponized Covid19 pandemic and the big profiteers like Pfizer and Moderna who have made massive investments in manufacturing mRNA jab facilities around the world and plan more. Please follow JikkyLeaks on Twitter as more details are emerg…
https://ctdbase.org/detail.go?acc=C048436&view=disease&sort=diseaseNmSort&type=chem&dir=asc
https://ctdbase.org/detail.go?acc=C048436&view=pathway&sort=pathwayAccFull&page=1&type=chem&dir=asc
https://daen.tga.gov.au/medicines-search/
Noémi Anna Nagy, Aram M de Haas, Teunis B H Geijtenbeek, Ronald van Ree, Sander W Tas, Yvette van Kooyk, Esther C de Jong. 2021. Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance. https://www.frontiersin.org/articles/10.3389/fimmu.2021.674048/full
Lymphadenopathy Danger from Endotoxin in Pfizer Jabs
BioNTech/Pfizer and complicit marketers of their Covid19 jab, including government departments around the globe, lied to the public when the said that the Lipid NanoParticles and the mRNA floating inside or outside them, would simply enter muscle cells in the arm, take them over to force them to become factories for Synthetic Spike generation and result…
Matti Lehtinen 1 , Jorma Paavonen, Cosette M Wheeler, Unnop Jaisamrarn, Suzanne M Garland, Xavier Castellsagué, S Rachel Skinner, Dan Apter, Paulo Naud, Jorge Salmerón, Song-Nan Chow, Henry Kitchener, Júlio C Teixeira, James Hedrick, Genara Limson, Anne Szarewski, Barbara Romanowski, Fred Y Aoki, Tino F Schwarz, Willy A J Poppe, Newton S De Carvalho, Maria Julieta V Germar, Klaus Peters, Adrian Mindel, Philippe De Sutter, F Xavier Bosch, Marie-Pierre David, Dominique Descamps, Frank Struyf, Gary Dubin; * HPV PATRICIA Study Group: I Denham, S M Garland, A Mindel, M O’Sullivan, S R Skinner, R Waddell, P De Sutter, W A J Poppe, W Tjalma, N S De Carvalho, P Naud, J C Teixeira, F Y Aoki, F Diaz-Mitoma, M Dionne, L Ferguson, M Miller, K Papp, B Ramjattan, B Romanowski, R Somani, D Apter, T Karppa, N Kudjoi, L Kyha-österlund, M Lehtinen, H Levanen, K Lönnberg, T Lunnas, L Niemi, J Paavonen, J Palmroth, T Petaja, S Rekonen, M Siitari-Mattila, L Tuomivaara, M Vilkki, K H Belling, T Gent, F Gieseking, T Grubert, W Harlfinger, W D Höpker, U Kohoutek, S Jensen-El Tobgui, G Merder, K Peters, S Schoenian, K Schulze, T F Schwarz, C Wackernagel, F Boselli, C A Liverani, J Salmerón, R Del Rosario-Raymundo, M J Germar, G Limson, G Villanueva, S Villanueva, J D Zamora, J Bajo, J Bayas, M Campins, X Castellsagué, M Castro, L Rodríguez, S N Chow, M H Yu, C C Yuan, S Angsuwathana, U Jaisamrarn, M Cruickshank, E Hakim, H Kitchener, D Lewis, A Szarewski, R Ackerman, M Caldwell, C Chambers, A Chatterjee, L Civitarese, L Demars, D Ferris, P Fine, S Gall, J Hedrick, W Herzig, W Huh, T Klein, W Koltun, J Lalezari, P Lee, S Luber, M Martens, W Nebel, C Peterson, K Pitts, J Rosen, W Rosenfeld, M Scutella, L Seidman, M Sperling, R Sperling, M Stager, J Stapleton, K Swenson, C Thoming, L Twiggs, A Waldbaum, C M Wheeler, E Zbella, A Camier, B Colau, V Xhenseval, S Genevrois, Z Issaka, P Marius, N Martens, T Ouammou, P Peeters, M Rahier, N Smoes, B Spiessens, A Meurée, N Houard, F Dessy, S Poncelet, A Tonglet, C Van Hoof, A S Vilain, T Zahaf, J Zima, E Alt, B Iskaros, A Limaye, X Liu-Jarin, R D Luff, M McNeeley, C Provenzano, B Winkler, A Molijn, W Quint, L Struijk, M Van de Sandt, L J Van Doorn, G Catteau, M-P David, T Zahaf, L Declerck, J Dupin, J-L Maroye, N Kiviat, K P Klugman, P Nieminen, C Bergeron, E Eisenstein, R Marks, T Nolan, S K Tay. 2012. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8.
Cosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, Anne Szarewski, Jorma Paavonen, Paulo Naud, Jorge Salmerón, Song-Nan Chow, Dan Apter, Henry Kitchener, Júlio C Teixeira, S Rachel Skinner, Unnop Jaisamrarn, Genara Limson, Barbara Romanowski, Fred Y Aoki, Tino F Schwarz, Willy A J Poppe, F Xavier Bosch, Diane M Harper, Warner Huh, Karin Hardt, Toufik Zahaf, Dominique Descamps, Frank Struyf, Gary Dubin, Matti Lehtinen; * HPV PATRICIA Study Group: I Denham, S M Garland, A Mindel, M O’Sullivan, S R Skinner, R Waddell, P De Sutter, W A J Poppe, W Tjalma, N S De Carvalho, P Naud, J C Teixeira, F Y Aoki, F Diaz-Mitoma, M Dionne, L Ferguson, M Miller, K Papp, B Ramjattan, B Romanowski, R Somani, D Apter, T Karppa, N Kudjoi, L Kyha-österlund, M Lehtinen, H Levanen, K Lönnberg, T Lunnas, L Niemi, J Paavonen, J Palmroth, T Petaja, S Rekonen, M Siitari-Mattila, L Tuomivaara, M Vilkki, K H Belling, T Gent, F Gieseking, T Grubert, W Harlfinger, W D Höpker, U Kohoutek, S Jensen-El Tobgui, G Merder, K Peters, S Schoenian, K Schulze, T F Schwarz, C Wackernagel, F Boselli, C A Liverani, J Salmerón, R Del Rosario-Raymundo, M J Germar, G Limson, G Villanueva, S Villanueva, J D Zamora, J Bajo, J Bayas, M Campins, X Castellsagué, M Castro, L Rodríguez, S N Chow, M H Yu, C C Yuan, S Angsuwathana, U Jaisamrarn, M Cruickshank, E Hakim, H Kitchener, D Lewis, A Szarewski, R Ackerman, M Caldwell, C Chambers, A Chatterjee, L Civitarese, L Demars, D Ferris, P Fine, S Gall, J Hedrick, W Herzig, W Huh, T Klein, W Koltun, J Lalezari, P Lee, S Luber, M Martens, W Nebel, C Peterson, K Pitts, J Rosen, W Rosenfeld, M Scutella, L Seidman, M Sperling, R Sperling, M Stager, J Stapleton, K Swenson, C Thoming, L Twiggs, A Waldbaum, C M Wheeler, E Zbella, A Camier, B Colau, V Xhenseval, S Genevrois, Z Issaka, P Marius, N Martens, T Ouammou, P Peeters, M Rahier, N Smoes, B Spiessens, A Meurée, N Houard, F Dessy, S Poncelet, A Tonglet, C Van Hoof, A S Vilain, T Zahaf, J Zima, E Alt, B Iskaros, A Limaye, X Liu-Jarin, R D Luff, M McNeeley, C Provenzano, B Winkler, A Molijn, W Quint, L Struijk, M Van de Sandt, L J Van Doorn, G Catteau, M-P David, T Zahaf, L Declerck, J Dupin, J-L Maroye, N Kiviat, K P Klugman, P Nieminen, C Bergeron, E Eisenstein, R Marks, T Nolan, S K Tay. 2012. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13(1):100-10. doi: 10.1016/S1470-2045(11)70287-X.
Anne Szarewski, S Rachel Skinner, Suzanne M Garland, Barbara Romanowski, Tino F Schwarz, Dan Apter, Song-Nan Chow, Jorma Paavonen, M Rowena Del Rosario-Raymundo, Julio C Teixeira, Newton S De Carvalho, Maria Castro-Sanchez, Xavier Castellsagué, Willy A J Poppe, Philippe De Sutter, Warner Huh, Archana Chatterjee, Wiebren A Tjalma, Ronald T Ackerman, Mark Martens, Kim A Papp, Jose Bajo-Arenas, Diane M Harper, Aureli Torné, Marie-Pierre David, Frank Struyf, Matti Lehtinen, Gary Dubin. 2013. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 208(9):1391-6. doi: 10.1093/infdis/jit360.
Frank Struyf, Brigitte Colau, Cosette M Wheeler, Paulo Naud, Suzanne Garland, Wim Quint, Song-Nan Chow, Jorge Salmerón, Matti Lehtinen, M Rowena Del Rosario-Raymundo, Jorma Paavonen, Júlio C Teixeira, Maria Julieta Germar, Klaus Peters, S Rachel Skinner, Genara Limson, Xavier Castellsagué, Willy A J Poppe, Brian Ramjattan, Terry D Klein, Tino F Schwarz, Archana Chatterjee, Wiebren A A Tjalma, Francisco Diaz-Mitoma, David J M Lewis, Diane M Harper, Anco Molijn, Leen-Jan van Doorn, Marie-Pierre David, Gary Dubin; HPV PATRICIA Study Group. 2015. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA. Clin Vaccine Immunol. 22(2):235-44. doi: 10.1128/CVI.00457-14.
Dan Apter 1 , Cosette M Wheeler 2 , Jorma Paavonen 3 , Xavier Castellsagué 4 , Suzanne M Garland 5 , S Rachel Skinner 6 , Paulo Naud 7 , Jorge Salmerón 8 , Song-Nan Chow 9 , Henry C Kitchener 10 , Julio C Teixeira 11 , Unnop Jaisamrarn 12 , Genara Limson 13 , Anne Szarewski 14 , Barbara Romanowski 15 , Fred Y Aoki 16 , Tino F Schwarz 17 , Willy A J Poppe 18 , F Xavier Bosch 19 , Adrian Mindel 20 , Philippe de Sutter 21 , Karin Hardt 22 , Toufik Zahaf 22 , Dominique Descamps 22 , Frank Struyf 22 , Matti Lehtinen 23 , Gary Dubin 24 ; * HPV PATRICIA Study Group: I Denham, S M Garland, A Mindel, M O’Sullivan, S R Skinner, P Naud, J C Teixeira, P De Sutter, W A J Poppe, F Y Aoki, P H Orr, F Diaz-Mitoma, M Dionne, L Ferguson, M Miller, P M Orr, K Papp, B Ramjattan, B Romanowski, R Somani, D Apter, T Karppa, N Kudjoi, M Kupari, M Lehtinen, L Niemi, J Paavonen, J Palmroth, T Petaja, U Romppanen, S Salmivesi, M Siitari-Mattila, S Svartsjo, L Tuomivaara, K H Belling, T Gent, F Gieseking, T Grubert, W Harlfinger, W D Hopker, S Jensen-El Tobgui, K Peters, S Schoenian, K Schulze, T Schwarz, C Liverani, G Mojana, J Salmeron, G Benitez, C Crisostomo, R Del Rosario-Raymundo, M J Germar, G Limson, J Raymundo, M C Remollino, G Villanueva, S Villanueva, J D Zamora, L Zamora, J Bajo, J Bayas, M Campins, X Castellsague, M Castro, C Centeno, L Rodriguez, A Torne, J A Vidart, S N Chow, M H Yu, C C Yuan, T -Y Chu, S Angsuwathana, U Jaisamrarn, K Wilawan, E Abdulhakim, M Cruickshank, S Govindraj, H Kitchener, D Lewis, I Pavel, R Pawa, A Szarewski, R Ackerman, K Ault, N Bennett, M Caldwell, C Chambers, A Chatterjee, L Demars, T Quinn De Santis, L Downs, D Ferris, P Fine, D Harper, J Hedrick, W Herzig, W Huh, C Hutchinson, L Kamemoto, T Klein, K P Klugman, W Koltun, A Kong, J Lalezari, P Lee, L Leeman, S Luber, M Martens, C Peterson, K Pitts, J Rosen, W Rosenfeld, M Scutella, L Seidman, M Sperling, M Stager, J T Stapleton, K Swenson, C Thoming, L Twiggs, S Tyring, A Waldbaum, C M Wheeler, E Zbella, N Kiviat, K P Klugman, P Nieminen, C Bergeron, E Eisenstein, R Marks, T Nolan, S K Tay, S Albers, P Bollaerts, A Camier, B Colau, A De Breyne, S Genevrois, N Martens, P Peeters, N Smoes, B Spiessens, F Tavares, A Meurée, N Houard, A Tonglet, S Vanden-Dunghen, A S Vilain, K R Ward, E Alt, B Iskaros, A Limaye, X Liu-Jarin, R D Luff, M McNeeley, C Provenzano, A Molijn, W Quint, L Struijk, M Van de Sandt, L J Van Doorn. 2015. Clin Vaccine Immunol. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. 22(4):361-73. doi: 10.1128/CVI.00591-14.
Corinne Willame, Dominique Rosillon, Julia Zima, Maria-Genalin Angelo, Anke L Stuurman, Hilde Vroling, Rachael Boggon, Eveline M Bunge, Manel Pladevall-Vila, Laurence Baril. November 2016. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Hum Vaccin Immunother. 12(11):2862-2871. doi: 10.1080/21645515.2016.1199308.
Autoimmune Diseases caused by Endotoxin in mRNA Jabs include Myocarditis, Pericarditis Lupus
Recently I briefly mentioned that Endotoxin, as found in every vial of Moderna and Pfizer jab, causes Autoimmune Diseases.
FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-guillain-barre-syndrome-gbs-warning-prescribing-information-rsv-vaccines-abrysvo-and
Samantha Anderer. 21 February 2025. FDA Issues Warning of Guillain-Barré Syndrome Risk for 2 RSV Vaccines. https://jamanetwork.com/journals/jama/fullarticle/2830753
Iatrogenesis becoming more and more apparent. Great research. Thanks.....I think 😄
HPV and Hepatitis A and B vaccines have unusual signals for immediate association with autoimmune diseases like POTS for HPV, lupus for all, plus several other neurological autoimmune diseases. They all share aluminum adjuvant (which is well known for neurotoxicity). Macrophages in mice carry injected aluminum past the blood brain barrier. Why is the signal for POTS with HPV so high???